Article

Agent delays bone metastases in men with castration-resistant prostate cancer

The RANK ligand inhibitor denosumab (XGEVA) may be able to prevent or at least delay multiple and/or symptomatic bone metastases in men with castration-resistant prostate cancer (CRPC) at high risk of bone metastases.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

© 2025 MJH Life Sciences

All rights reserved.